INVESTIGACION

PROYECTO DE INVESTIGACION: CASO PFIZER

CASELINKS

Batch 17 of 28

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

92. Searchlink: `www-pacer-usa`

The Standard Model: The model for PACER (Public Access to Court Electronic Records) is to search US federal court dockets to find the litigation history for a company or individual, which is essential for building a comprehensive risk profile ¹.
Customisation for the PFIZER CASE:
- Objective: To find any private antitrust lawsuits filed against Pfizer or Flynn Pharma in the US courts regarding “excessive pricing” or other anti-competitive conduct.
- Search Strategy: We will conduct targeted searches on the PACER database for civil cases where “Pfizer Inc.” or “Flynn Pharma” are listed as defendants. Our search will use a combination of keywords such as "antitrust", "excessive pricing", "monopolization", "phenytoin", and "Sherman Act".
- Supporting Online Intelligence: An online search for “US antitrust lawsuit against Pfizer” reveals past litigation concerning other drugs, such as Neurontin. These news reports and law firm summaries can help identify key case numbers and legal arguments to look for in PACER.
- Expected Outcome: A dossier of US litigation against the defendant companies. Finding existing private antitrust cases in the US would provide a trove of legal arguments, economic expert reports, and potentially unsealed discovery documents that could be directly relevant and highly persuasive for our own UK-based collective action.

93. Searchlink: `www-usaspending-gov`

The Standard Model: The procedure for USAspending.gov is to search its database to see if a specific company has been awarded contracts from the US federal government, detailing the awarding agency, value, and purpose of the contract ².
Customisation for the PFIZER CASE:
- Objective: To determine if Pfizer and Flynn Pharma are also major suppliers of medicines to the US government.
- Search Strategy: We will search the USAspending.gov database for all federal contracts awarded to “Pfizer Inc.” and “Flynn Pharma”. We will specifically look for large supply contracts from the Department of Health and Human Services (HHS), the Department of Veterans Affairs (VA), and the Department of Defense (DoD), which are all major purchasers of medicines.
- Supporting Online Intelligence: A search for news articles about major pharmaceutical supply contracts between these companies and the US government, for instance for COVID-19 vaccines or other major health initiatives, can provide context on their role as federal suppliers.
- Expected Outcome: A report detailing the contractual relationship between the defendant companies and the US government. This information can be used to construct a powerful public interest argument: that these companies, while benefiting from billions in public contracts, are simultaneously harming the public in other jurisdictions (the UK) by engaging in anti-competitive practices that inflate drug prices for other public health systems.

94. Searchlink: `www-global-branddb-wipo-int`

The Standard Model: The model for the WIPO Global Brand Database is to search for all trademarks owned by specific companies or within an industry to map branding strategies and commercial footprints ³.
Customisation for the PFIZER CASE:
- Objective: To identify all the registered brand names associated with the specific drug involved in the case (phenytoin) across different jurisdictions.
- Search Strategy: We will conduct searches on the WIPO database for the well-known brand names of phenytoin, such as "Dilantin" or "Epanutin". We will analyze who owns these trademarks and in which countries they are registered.
- Supporting Online Intelligence: Not required for this direct search, as WIPO is the primary global source for this information.
- Expected Outcome: A report detailing the global trademark portfolio for the drug at the heart of our case. This helps to confirm the brand’s owner and its global market presence, which is a foundational part of defining the relevant product market for our competition claim. The fact that the drug was “de-branded” in the UK makes this global branding information particularly relevant.

95. Searchlink: `www-register-openownership-org-search`

The Standard Model: The doctrine for the OpenOwnership register is to use its data to cut through complex corporate structures and identify the Ultimate Beneficial Owners (UBOs) of a company, which is critical for accountability ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the ownership structure of the defendant companies, particularly the privately-held Flynn Pharma.
- Search Strategy: We will conduct a deep search on the OpenOwnership register for “Flynn Pharma Limited”. While data on UK private companies may be limited, any declared ownership information is valuable for identifying the individuals behind the company. For Pfizer, a major public company, this is less relevant than institutional shareholder data, but we will still check for any complex holding structures declared in the register.
- Supporting Online Intelligence: We will search for news articles from financial publications (like the Financial Times) or news reports from the time of the original CMA investigation that may have investigated the ownership of Flynn Pharma.
- Expected Outcome: An ownership profile for each defendant company. For the privately held Flynn Pharma, identifying the controlling individuals is crucial for accountability and for the media narrative. It allows us to put a human face on the company that profited from the price hike.

96. Searchlink: `www-infocif-es`

The Standard Model: Infocif is a commercial provider of Spanish company data, used to get detailed financial reports, director information, and corporate linkage data that supplements official registry information ⁵.
Customisation for the PFIZER CASE:
- Objective: To obtain detailed financial reports for the Spanish subsidiaries of Pfizer to support a potential parallel damages calculation in Spain.
- Search Strategy: We will use Infocif to pull the full financial statements (cuentas anuales) for Pfizer’s main Spanish entity, “Pfizer, S.L.U.”.
- Supporting Online Intelligence: A search for Spanish pharmaceutical industry news from publications like “Correo Farmacéutico” or “PM Farma” can provide context on Pfizer’s market share and key products specifically within Spain, helping us to interpret the financial data.
- Expected Outcome: A detailed financial analysis of Pfizer’s Spanish operations. We can analyze their revenue from phenytoin sodium (if available) and other drugs, their declared profit margins in Spain, and their overall financial health. This is critical data for potentially expanding our action to include the Spanish National Health System, a major victim of any pan-European overpricing strategy.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹¹¹¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ²²²².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³³³³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴⁴⁴⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹¹¹¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ²²²².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³³³³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴⁴⁴⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

82, 83, 84 & 85. Searchlinks: `www-bidstats-uk`, `www-oscartool-gov-uk`, and their associated links

The Standard Model: The doctrine for these platforms is to use them in combination. OSCAR (publicsector.co.uk) is used to identify the structure and key personnel of UK public bodies ¹, while Bidstats.uk is used to analyze their historical contract awards to understand procurement patterns and costs ².
Customisation for the PFIZER CASE:
- Objective: To identify the key decision-makers within the NHS responsible for pharmaceutical spending and to build a cost model for the legal services required for our public contract proposal.
- Search Strategy: This refined strategy combines the tools:
  1. First, using OSCAR, we will search for specific senior job titles within NHS England and the Department of Health, such as "Chief Pharmaceutical Officer" or "Director of Medicines Value and Access", to identify the key client contacts.
  2. Second, using Bidstats, we will search for any UK public contracts awarded by government bodies (like the CMA or Government Legal Department) for "competition law legal advisory services" or "antitrust litigation support".
- Supporting Online Intelligence: We will use professional networking sites like LinkedIn to verify the names and professional backgrounds of the individuals identified through OSCAR. We will also search legal directories like The Legal 500 or Chambers & Partners ³³³³ for their rankings of top UK public procurement and competition law firms, who are the likely winners of the contracts found on Bidstats.
- Expected Outcome: This combined approach will produce two key outputs:
  - A specific list of named individuals who are the key decision-makers for pharmaceutical spending within the NHS, allowing for highly targeted engagement.
  - A database of real-world costs for the specialist legal work required to manage a large-scale competition damages claim, providing a credible budget for the legal component of our public contract proposal.

86. Searchlink: `www-wto-disp-settlement`

The Standard Model: The WTO dispute settlement database is used to find legal precedents where domestic regulations have been challenged as illegal trade barriers, forming the basis of a “USP-to-WTO” strategic play ⁴.
Customisation for the PFIZER CASE:
- Objective: To find any WTO disputes related to the intersection of intellectual property rights (patents) and competition law in the pharmaceutical sector.
- Search Strategy: We will search the WTO dispute database for any cases where a country’s patent laws or its competition enforcement related to pharmaceuticals was challenged by another member state as being a violation of the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights).
- Supporting Online Intelligence: An online search for “WTO TRIPS pharmaceutical dispute” will find information and analysis on landmark cases, such as those concerning compulsory licensing for essential medicines or disputes between the US, EU, and developing countries over pharmaceutical patent protection.
- Expected Outcome: An intelligence report on how international trade law, via the WTO, handles conflicts between patent protection and competition principles. This provides high-level legal context for our case, demonstrating that the tension between intellectual property rights and competition—which is the very issue at the heart of “excessive pricing” for off-patent drugs—is a subject of significant international legal and political debate.

87. Searchlink: `www-uk-parlm-petitions`

The Standard Model: The model for the UK Parliament’s petitions website is to search for past and present petitions on a specific topic to gauge the level of public concern and political engagement on that issue ¹.
Customisation for the PFIZER CASE:
- Objective: To assess the level of UK public and political concern regarding high drug prices and the affordability of medicines for the NHS.
- Search Strategy: We will search the petitions.parliament.uk website for any petitions related to "NHS drug costs", "prescription charges", "pharmaceutical prices", or "access to medicines". We will analyze the number of signatures each petition received and, crucially, the official response published by the UK Government.
- Supporting Online Intelligence: A search for campaigns by major UK patient advocacy groups or health charities (such as Cancer Research UK or the Patients Association) often reveals that they actively direct their supporters to sign these official government petitions, confirming that these petitions are a good proxy for active public concern.
- Expected Outcome: An intelligence report on the political salience of high medicine costs in the UK. This provides hard evidence of public concern about the underlying harm our case addresses. This supports the public interest dimension of our claim and can be used in communications with our NHS client to demonstrate that taking action is politically popular.

88. Searchlink: `www-usa-oge-gov`

The Standard Model: The model for using the US Office of Government Ethics (OGE) website is to study its framework, rules, and advisory opinions to understand what constitutes the “gold standard” for ethical conduct in government ².
Customisation for the PFIZER CASE:
- Objective: To find best-practice ethical guidelines for public officials who deal with powerful, heavily regulated industries, which can be used as a benchmark for our engagement with European health authorities.
- Search Strategy: We will search the OGE’s advisory opinions and educational materials for guidance on how public officials should manage relationships and avoid conflicts of interest with industries that have significant lobbying power, such as the pharmaceutical sector.
- Supporting Online Intelligence: Searching for “US FDA ethics rules” or “HHS ethics guidelines for industry meetings” will provide context on the specific standards applied to US health regulators when they interact with pharmaceutical companies.
- Expected Outcome: A report on the “gold standard” for ethical conduct in government-industry relations. This can be used to frame our engagement with both EU and national health officials. It also allows us to subtly benchmark their conduct against these high ethical standards, particularly in the context of drug pricing negotiations and competition enforcement.

89. Searchlink: `www-usa-congress-lobby-discl`

The Standard Model: The model for the US Congress Lobbying Disclosure database is to search for lobbying reports filed by specific companies to see which legislation they are trying to influence, which government agencies they are targeting, and how much they are spending ³.
Customisation for the PFIZER CASE:
- Objective: To identify the US lobbying activities of the major pharmaceutical companies involved in “excessive pricing” cases, including Pfizer.
- Search Strategy: We will search the database for lobbying reports filed by Pfizer and their main industry association, PhRMA. We will analyze the specific bills they are lobbying on regarding “patent reform”, “drug pricing”, and “antitrust”, and note their reported expenditures.
- Supporting Online Intelligence: Reports from US-based watchdog groups like the Center for Responsive Politics (OpenSecrets) often provide high-level analysis and data visualizations of lobbying by the pharmaceutical sector, which can help focus our search on the most active players and key issues.
- Expected Outcome: An intelligence report detailing the US lobbying priorities of the defendant company. This helps build a global profile of their political influencing strategy and their stance on competition and patent law, which provides valuable context for our case.

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

The Standard Model: The model is to use global patent databases like Espacenet and the USPTO to investigate the innovation landscape for a specific technology and to identify the intellectual property assets of key corporate players ⁴.
Customisation for the PFIZER CASE:
- Objective: To investigate the patent history of phenytoin to understand why it was possible for Pfizer to implement such a large price increase.
- Search Strategy: Our strategy is to search these patent databases for the original patents for “phenytoin”. We will focus on identifying the original inventor and the date of patent expiry. This is a historical search to prove that the drug has long been off-patent. We will also search for any secondary patents filed by Pfizer related to the drug’s formulation or manufacturing process.
- Supporting Online Intelligence: An online search for the “history of phenytoin” or “phenytoin patent expiry date” confirms that the drug was first synthesized in 1908 and has been off-patent for many decades. This is a critical fact.
- Expected Outcome: A report detailing the patent history of phenytoin. This evidence is crucial for our “excessive pricing” argument. It proves that the price hike was not related to any ongoing IP protection or recent innovation, but was purely an exploitation of the drug’s “de-branded” status and the lack of competition, which is the very definition of an abuse of dominance.

67. Searchlink: `www-casetracker-gov-uk`

The Standard Model: The model for a government case tracker is to monitor the progress of specific ongoing government projects, investigations, or legal cases ¹.
Customisation for the PFIZER CASE:
- Objective: To benchmark the project management and public reporting of large-scale government litigation or consumer redress schemes in the UK.
- Search Strategy: We will search the Casetracker system for any major litigation cases where the Department of Health or the NHS are named parties, or for any large-scale consumer redress schemes that have been managed by UK regulators like the CMA. We will analyze their public timelines, key milestones, and the level of detail provided to the public.
- Supporting Online Intelligence: An online search for “NHS litigation annual report” or “CMA consumer redress scheme report” can provide the names of major cases or schemes that we can then look for specifically within the tracker system.
- Expected Outcome: A case study of how the UK government manages and reports on major litigation. This provides a credible, real-world template for the project management and governance section of our public contract proposal to the NHS, demonstrating professionalism and an understanding of the reporting and transparency requirements expected in public sector projects.

68. Searchlink: `www.hl.co.uk/funds`

The Standard Model: The model for investment platforms like Hargreaves Lansdown is to use their fund screening tools to identify institutional investors in specific companies or sectors, revealing where “smart money” is positioned ².
Customisation for the PFIZER CASE:
- Objective: To identify the major institutional investors, such as pension funds and large asset managers, who hold significant shares in the defendant pharmaceutical companies.
- Search Strategy: We will use the fund screener on www.hl.co.uk/funds to identify the top UK and European investment funds with large holdings in the publicly listed defendant companies (e.g., Pfizer, GSK).
- Supporting Online Intelligence: A crucial supporting action is to search for the “Stewardship Reports” or “Responsible Investment Policies” published by the major asset managers we identify (e.g., BlackRock, Legal & General, Schroders). These reports often detail their policies on corporate governance and how they engage with companies on legal, ethical, and reputational risks ³.
- Expected Outcome: A prioritized list of the most powerful shareholders in the defendant companies. These institutions are key targets for a sophisticated engagement campaign. We can present our case to them, highlighting the significant financial and reputational risks their portfolio companies are exposed to due to the “excessive pricing” litigation, and pressure them to encourage the companies towards a fair settlement.

69. Searchlink: `www-causelist-gov-uk`

The Standard Model: The model for a court’s Cause List is to perform daily checks to monitor the scheduling of upcoming hearings, judicial assignments, and the progress of active litigation ⁴.
Customisation for the PFIZER CASE:
- Objective: To tactically monitor the daily procedural progress of our own legal action once it has been filed in the UK.
- Search Strategy: Once our collective action is filed with the UK’s Competition Appeal Tribunal (CAT), this platform becomes an essential daily tool. The strategy is to search the cause list at www.causelist.justice.gov.uk every morning for our specific case name or number.
- Supporting Online Intelligence: Not required for this tactical monitoring task.
- Expected Outcome: A real-time case management dashboard. This ensures our legal team never misses a hearing, a filing deadline, or a judicial order. In complex, multi-year litigation, this rigorous daily monitoring is critical for professional and effective case management and for reacting instantly to any procedural developments.

70. Searchlink: `www-find-tender-service-gov-uk`

The Standard Model: The procedure for UK public procurement portals like Find a Tender is to search for past and present tender opportunities to understand government purchasing patterns and to find contract award notices which contain details on value and scope ⁵.
Customisation for the PFIZER CASE:
- Objective: To find real-world cost data for the highly specialized services needed to run our collective action, such as expert economic consulting and claims administration.
- Search Strategy: We will search the www.find-tender.service.gov.uk portal for any UK government or NHS tenders for "competition economics expert services", "antitrust damages quantification", or "class action claims administration". We will analyze the contract specifications to understand the scope of work and the award notices to find the contract values.
- Supporting Online Intelligence: A search for firms that specialize in claims administration for UK class actions (such as Epiq, Kroll, or Rust Consulting) can identify the key suppliers who would likely bid on such tenders, providing a sense of market rates. This connects to the ecosystem of litigation service providers discussed in the HOW 2 SELL MY LITIGATION... document ⁶.
- Expected Outcome: A database of real-world contract values for the specific, high-cost expert services required for our project. This provides a credible, evidence-based financial model for our public contract proposal to the NHS, allowing us to justify the budget required to manage the claim successfully.

71. Searchlink: `www-lobbyfacts-eu`

The Standard Model: The doctrine for LobbyFacts.eu is to use its database to track the lobbying expenditures, personnel, and meeting history of organizations trying to influence the EU institutions in Brussels ⁷.
Customisation for the PFIZER CASE:
- Objective: To map the lobbying efforts of the defendant pharmaceutical companies and their trade associations in Brussels.
- Search Strategy: We will conduct a detailed search on LobbyFacts.eu for the profiles of Pfizer, Flynn Pharma, and their primary European trade association, EFPIA (European Federation of Pharmaceutical Industries and Associations). We will analyze their declared lobbying expenditures and their history of meetings with officials from the European Commission’s DG COMP (Competition) and DG SANTE (Health).
- Supporting Online Intelligence: We will cross-reference this with reports from Brussels-based transparency NGOs (like Corporate Europe Observatory or Transparency International EU) that have specifically investigated pharmaceutical industry lobbying. These reports often provide narratives and context that are missing from the raw data.
- Expected Outcome: A detailed intelligence report on the industry’s lobbying strategy in Brussels. This helps us understand their political priorities, the arguments they use with policymakers, and the officials they target. This is crucial for developing our own counter-messaging and for our strategic engagement with EU institutions.

82, 83, 84 & 85. Searchlinks: `www-bidstats-uk`, `www-oscartool-gov-uk`, and their associated links

The Standard Model: The doctrine for these platforms is to use them in combination. OSCAR (publicsector.co.uk) is used to identify the structure and key personnel of UK public bodies ¹, while Bidstats.uk is used to analyze their historical contract awards to understand procurement patterns and costs ².
Customisation for the PFIZER CASE:
- Objective: To identify the key decision-makers within the NHS responsible for pharmaceutical spending and to build a cost model for the legal services required for our public contract proposal.
- Search Strategy: This refined strategy combines the tools:
  1. First, using OSCAR, we will search for specific senior job titles within NHS England and the Department of Health, such as "Chief Pharmaceutical Officer" or "Director of Medicines Value and Access", to identify the key client contacts.
  2. Second, using Bidstats, we will search for any UK public contracts awarded by government bodies (like the CMA or Government Legal Department) for "competition law legal advisory services" or "antitrust litigation support".
- Supporting Online Intelligence: We will use professional networking sites like LinkedIn to verify the names and professional backgrounds of the individuals identified through OSCAR. We will also search legal directories like The Legal 500 or Chambers & Partners ³ for their rankings of top UK public procurement and competition law firms, who are the likely winners of the contracts found on Bidstats.
- Expected Outcome: This combined approach will produce two key outputs:
  - A specific list of named individuals who are the key decision-makers for pharmaceutical spending within the NHS, allowing for highly targeted engagement.
  - A database of real-world costs for the specialist legal work required to manage a large-scale competition damages claim, providing a credible budget for the legal component of our public contract proposal.

86. Searchlink: `www-wto-disp-settlement`

The Standard Model: The WTO dispute settlement database is used to find legal precedents where domestic regulations have been challenged as illegal trade barriers, forming the basis of a “USP-to-WTO” strategic play ⁴.
Customisation for the PFIZER CASE:
- Objective: To find any WTO disputes related to the intersection of intellectual property rights (patents) and competition law in the pharmaceutical sector.
- Search Strategy: We will search the WTO dispute database for any cases where a country’s patent laws or its competition enforcement related to pharmaceuticals was challenged by another member state as being a violation of the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights).
- Supporting Online Intelligence: An online search for “WTO TRIPS pharmaceutical dispute” will find information and analysis on landmark cases, such as those concerning compulsory licensing for essential medicines or disputes between the US, EU, and developing countries over pharmaceutical patent protection.
- Expected Outcome: An intelligence report on how international trade law, via the WTO, handles conflicts between patent protection and competition principles. This provides high-level legal context for our case, demonstrating that the tension between intellectual property rights and competition—which is the very issue at the heart of “excessive pricing” for off-patent drugs—is a subject of significant international legal and political debate.

67. Searchlink: `www-casetracker-gov-uk`

The Standard Model: The model for a government case tracker is to monitor the progress of specific ongoing government projects, investigations, or legal cases¹.
Customisation for the PFIZER CASE:
- Objective: To benchmark the project management and public reporting of large-scale government litigation or consumer redress schemes in the UK.
- Search Strategy: We will search the Casetracker system for any major litigation cases where the Department of Health or the NHS are named parties, or for any large-scale consumer redress schemes that have been managed by UK regulators like the CMA. We will analyze their public timelines, key milestones, and the level of detail provided to the public.
- Supporting Online Intelligence: An online search for “NHS litigation annual report” or “CMA redress scheme report” can provide the names of major cases or schemes that we can then look for specifically within the tracker system.
- Expected Outcome: A case study of how the UK government manages and reports on major litigation. This provides a credible, real-world template for the project management and governance section of our public contract proposal to the NHS, demonstrating professionalism and an understanding of the reporting and transparency requirements expected in public sector projects.

68. Searchlink: `www.hl.co.uk/funds`

The Standard Model: The model for investment platforms like Hargreaves Lansdown is to use their fund screening tools to identify institutional investors in specific companies or sectors, revealing where “smart money” is positioned².
Customisation for the PFIZER CASE:
- Objective: To identify the major institutional investors, such as pension funds and large asset managers, who hold significant shares in the defendant pharmaceutical companies.
- Search Strategy: We will use the fund screener on www.hl.co.uk/funds to identify the top UK and European investment funds with large holdings in the publicly listed defendant companies (e.g., Pfizer, GSK).
- Supporting Online Intelligence: A crucial supporting action is to search for the “Stewardship Reports” or “Responsible Investment Policies” published by the major asset managers we identify (e.g., BlackRock, Legal & General, Schroders). These reports often detail their policies on corporate governance and how they engage with companies on legal, ethical, and reputational risks ³.
- Expected Outcome: A prioritized list of the most powerful shareholders in the defendant companies. These institutions are key targets for a sophisticated engagement campaign. We can present our case to them, highlighting the significant financial and reputational risks their portfolio companies are exposed to due to the “excessive pricing” litigation, and pressure them to encourage the companies towards a fair settlement.

69. Searchlink: `www-causelist-gov-uk`

The Standard Model: The model for a court’s Cause List is to perform daily checks to monitor the scheduling of upcoming hearings, judicial assignments, and the progress of active litigation⁴.
Customisation for the PFIZER CASE:
- Objective: To tactically monitor the daily procedural progress of our own legal action once it has been filed in the UK.
- Search Strategy: Once our collective action is filed with the UK’s Competition Appeal Tribunal (CAT), this platform becomes an essential daily tool. The strategy is to search the cause list at www.causelist.justice.gov.uk every morning for our specific case name or number.
- Supporting Online Intelligence: Not required for this tactical monitoring task.
- Expected Outcome: A real-time case management dashboard. This ensures our legal team never misses a hearing, a filing deadline, or a judicial order. In complex, multi-year litigation, this rigorous daily monitoring is critical for professional and effective case management and for reacting instantly to any procedural developments.

70. Searchlink: `www-find-tender-service-gov-uk`

The Standard Model: The procedure for UK public procurement portals like Find a Tender is to search for past and present tender opportunities to understand government purchasing patterns and to find contract award notices which contain details on value and scope⁵.
Customisation for the PFIZER CASE:
- Objective: To find real-world cost data for the highly specialized services needed to run our collective action, such as expert economic consulting and claims administration.
- Search Strategy: We will search the www.find-tender.service.gov.uk portal for any UK government or NHS tenders for "competition economics expert services", "antitrust damages quantification", or "class action claims administration". We will analyze the contract specifications to understand the scope of work and the award notices to find the contract values.
- Supporting Online Intelligence: A search for firms that specialize in claims administration for UK class actions (such as Epiq, Kroll, or Rust Consulting) can identify the key suppliers who would likely bid on such tenders, providing a sense of market rates.
- Expected Outcome: A database of real-world contract values for the specific, high-cost expert services required for our project. This provides a credible, evidence-based financial model for our public contract proposal to the NHS, allowing us to justify the budget required to manage the claim successfully.

71. Searchlink: `www-lobbyfacts-eu`

The Standard Model: The doctrine for LobbyFacts.eu is to use its database to track the lobbying expenditures, personnel, and meeting history of organizations trying to influence the EU institutions in Brussels ⁶.
Customisation for the PFIZER CASE:
- Objective: To map the lobbying efforts of the defendant pharmaceutical companies and their trade associations in Brussels.
- Search Strategy: We will conduct a detailed search on LobbyFacts.eu for the profiles of Pfizer, Flynn Pharma, and their primary European trade association, EFPIA (European Federation of Pharmaceutical Industries and Associations). We will analyze their declared lobbying expenditures and their history of meetings with officials from the European Commission’s DG COMP (Competition) and DG SANTE (Health).
- Supporting Online Intelligence: We will cross-reference this with reports from Brussels-based transparency NGOs (like Corporate Europe Observatory or Transparency International EU) that have specifically investigated pharmaceutical industry lobbying. These reports often provide narratives and context that are missing from the raw data.
- Expected Outcome: A detailed intelligence report on the industry’s lobbying strategy in Brussels. This helps us understand their political priorities, the arguments they use with policymakers, and the officials they target. This is crucial for developing our own counter-messaging and for our strategic engagement with EU institutions.

67. Searchlink: `www-casetracker-gov-uk`

The Standard Model: The model for a government case tracker is to monitor the progress of specific ongoing government projects, investigations, or legal cases¹¹¹¹.
Customisation for the PFIZER CASE:
- Objective: To benchmark the project management and public reporting of large-scale government litigation or consumer redress schemes in the UK.
- Search Strategy: We will search the Casetracker system for any major litigation cases where the Department of Health or the NHS are named parties, or for any large-scale consumer redress schemes that have been managed by UK regulators like the CMA. We will analyze their public timelines, key milestones, and the level of detail provided to the public.
- Supporting Online Intelligence: An online search for “NHS litigation annual report” or “CMA consumer redress scheme report” can provide the names of major cases or schemes that we can then look for specifically within the tracker system.
- Expected Outcome: A case study of how the UK government manages and reports on major litigation. This provides a credible, real-world template for the project management and governance section of our public contract proposal to the NHS, demonstrating professionalism and an understanding of the reporting and transparency requirements expected in public sector projects.

68. Searchlink: `www.hl.co.uk/funds`

The Standard Model: The model for investment platforms like Hargreaves Lansdown is to use their fund screening tools to identify institutional investors in specific companies or sectors, revealing where “smart money” is positioned².
Customisation for the PFIZER CASE:
- Objective: To identify the major institutional investors, such as pension funds and large asset managers, who hold significant shares in the defendant pharmaceutical companies.
- Search Strategy: We will use the fund screener on www.hl.co.uk/funds to identify the top UK and European investment funds with large holdings in the publicly listed defendant companies (e.g., Pfizer, GSK, Teva).
- Supporting Online Intelligence: A crucial supporting action is to search for the “Stewardship Reports” or “Responsible Investment Policies” published by the major asset managers we identify (e.g., BlackRock, Legal & General, Schroders). These reports often detail their policies on corporate governance and how they engage with companies on legal, ethical, and reputational risks.
- Expected Outcome: A prioritized list of the most powerful shareholders in the defendant companies. These institutions are key targets for a sophisticated engagement campaign. We can present our case to them, highlighting the significant financial and reputational risks their portfolio companies are exposed to due to the “excessive pricing” litigation, and pressure them to encourage the companies towards a fair settlement.

69. Searchlink: `www-causelist-gov-uk`

The Standard Model: The model for a court’s Cause List is to perform daily checks to monitor the scheduling of upcoming hearings, judicial assignments, and the progress of active litigation³³³³.
Customisation for the PFIZER CASE:
- Objective: To tactically monitor the daily procedural progress of our own legal action once it has been filed in the UK.
- Search Strategy: Once our collective action is filed with the UK’s Competition Appeal Tribunal (CAT), this platform becomes an essential daily tool. The strategy is to search the cause list at www.causelist.justice.gov.uk every morning for our specific case name or number.
- Supporting Online Intelligence: Not required for this tactical monitoring task.
- Expected Outcome: A real-time case management dashboard. This ensures our legal team never misses a hearing, a filing deadline, or a judicial order. In complex, multi-year litigation, this rigorous daily monitoring is critical for professional and effective case management and for reacting instantly to any procedural developments.

70. Searchlink: `www-find-tender-service-gov-uk`

The Standard Model: The procedure for UK public procurement portals like Find a Tender is to search for past and present tender opportunities to understand government purchasing patterns and to find contract award notices which contain details on value and scope⁴.
Customisation for the PFIZER CASE:
- Objective: To find real-world cost data for the highly specialized services needed to run our collective action, such as expert economic consulting and claims administration.
- Search Strategy: We will search the www.find-tender.service.gov.uk portal for any UK government or NHS tenders for "competition economics expert services", "antitrust damages quantification", or "class action claims administration". We will analyze the contract specifications to understand the scope of work and the award notices to find the contract values.
- Supporting Online Intelligence: A search for firms that specialize in claims administration for UK class actions (such as Epiq, Kroll, or Rust Consulting) can identify the key suppliers who would likely bid on such tenders, providing a sense of market rates.
- Expected Outcome: A database of real-world contract values for the specific, high-cost expert services required for our project. This provides a credible, evidence-based financial model for our public contract proposal to the NHS, allowing us to justify the budget required to manage the claim successfully.

71. Searchlink: `www-lobbyfacts-eu`

The Standard Model: The doctrine for LobbyFacts.eu is to use its database to track the lobbying expenditures, personnel, and meeting history of organizations trying to influence the EU institutions in Brussels.
Customisation for the PFIZER CASE:
- Objective: To map the lobbying efforts of the defendant pharmaceutical companies and their trade associations in Brussels.
- Search Strategy: We will conduct a detailed search on LobbyFacts.eu for the profiles of Pfizer, Flynn Pharma, and their primary European trade association, EFPIA (European Federation of Pharmaceutical Industries and Associations). We will analyze their declared lobbying expenditures and their history of meetings with officials from the European Commission’s DG COMP (Competition) and DG SANTE (Health).
- Supporting Online Intelligence: We will cross-reference this with reports from Brussels-based transparency NGOs (like Corporate Europe Observatory or Transparency International EU) that have specifically investigated pharmaceutical industry lobbying. These reports often provide narratives and context that are missing from the raw data.
- Expected Outcome: A detailed intelligence report on the industry’s lobbying strategy in Brussels. This helps us understand their political priorities, the arguments they use with policymakers, and the officials they target. This is crucial for developing our own counter-messaging and for our strategic engagement with EU institutions.

62. Searchlink: `64816` (Internal Document)

The Standard Model: Internal files represent the core proprietary analysis or the central Unsolicited Proposal (USP) of a COCOO project¹. The model dictates that all external intelligence gathering is designed to support, validate, and provide the evidence base for the contents of these internal documents².
Customisation for the PFIZER CASE:
- Objective: To use the specific, confidential information within internal file 64816 to direct and focus our external investigation into the Pfizer/Flynn Pharma “excessive pricing” case.
- Search Strategy: The action is to retrieve the designated file from COCOO’s internal systems. For the purpose of this case, we will assume the file contains a detailed economic analysis or a confidential expert opinion that models the “but-for” price of phenytoin sodium capsules—the price that would have prevailed in a competitive market.
- Supporting Online Intelligence: Not applicable for an internal file.
- Expected Outcome: A highly targeted investigation plan based on the internal model’s data needs. All external research on platforms like www-gov-uk-search-advanced will be focused on finding the public data on NHS expenditure and prescription volumes needed to populate this economic model. This process turns our internal analysis into a fully evidenced expert report ready for litigation.

63. Searchlink: `www-ec-europa-eu-haveyoursay`

The Standard Model: The European Commission’s “Have your say” portal is a direct channel for COCOO to influence the direction of EU policy and to find stakeholder feedback on legislation³³³.
Customisation for the PFIZER CASE:
- Objective: To find evidence of prior complaints or concerns raised by patient groups or health services across Europe about excessive pricing of off-patent medicines.
- Search Strategy: We will search the portal for any past public consultations on the “EU Pharmaceutical Strategy,” “access to medicines,” or “competition in the pharmaceutical sector.” Our strategy is to download and analyze the specific submissions made by pan-European patient groups (e.g., European Patients’ Forum) or hospital associations.
- Supporting Online Intelligence: An online search for “BEUC report on medicine prices” (BEUC is the European Consumer Organisation) will likely find public reports or summaries of their positions, helping to locate key documents and arguments.
- Expected Outcome: A report containing direct quotes and evidence from patient and consumer groups across Europe. This will prove that the harm caused by excessive pricing is a widespread, pan-European concern. This supports the public interest dimension of our case and demonstrates that our action against Pfizer is addressing a systemic problem.

64. Searchlink: `www-caselaw-nationalarchives-gov-uk`

The Standard Model: The National Archives case law service is a key resource for accessing judgments from various UK courts, particularly those involving challenges to public bodies⁴⁴⁴.
Customisation for the PFIZER CASE:
- Objective: To find foundational UK case law on the legal test for “excessive pricing” as a form of abuse of a dominant position.
- Search Strategy: We will search the archives for landmark UK cases that have established the principles for determining when a price is so high that it becomes an illegal abuse. Keywords will include "excessive pricing", "abuse of dominance", "Chapter II prohibition", and "Competition Act 1998".
- Supporting Online Intelligence: Searching for legal commentary on the CMA v Flynn and Pfizer case itself, as it has progressed through the courts, will provide expert analysis on how the legal tests for excessive pricing have been interpreted and applied by the highest UK courts.
- Expected Outcome: A foundational legal brief on the methodology for proving excessive pricing under UK competition law. This is essential for our legal team to structure their arguments and for instructing our economic experts on the specific evidence they need to provide to meet the legal tests established by the courts.

65. Searchlink: `www-violationtracker-uk`

The Standard Model: Violation Tracker UK is a comprehensive database of regulatory infringements and penalties in the UK, with a powerful advanced search function that allows filtering by Offence Group (e.g., competition-related offences, consumer-protection-related offences)⁵⁵⁵.
Customisation for the PFIZER CASE:
- Objective: To investigate the broader compliance record of Pfizer and Flynn Pharma in the UK, looking for patterns of misconduct that go beyond this specific competition case.
- Search Strategy: Our refined strategy is to search Violation Tracker UK for the UK entities “Pfizer Limited” and “Flynn Pharma Limited”. We will broaden the search beyond just competition offences to include any “marketing and advertising offences,” “health-care-related offenses,” or “false claims/statements” violations.
- Supporting Online Intelligence: A search for “Pfizer fined UK” or “PMCPA Pfizer” can reveal past enforcement actions by UK bodies like the Prescription Medicines Code of Practice Authority (PMCPA) for breaches of the pharmaceutical marketing code.
- Expected Outcome: A comprehensive risk and compliance profile for each defendant company. A history of violations in other areas, such as illegal marketing, helps to build a compelling narrative of a corporate culture that prioritizes profits over rules. This narrative can be used strategically in the public relations campaign surrounding the case to frame the defendants as untrustworthy actors.

66. Searchlink: `www-business-property-courts-uk`

The Standard Model: The model for the archives of the UK’s specialist Business and Property Courts is to search for judgments in high-value, complex commercial disputes that may provide persuasive precedents⁶.
Customisation for the PFIZER CASE:
- Objective: To find UK case law that deals with the complex calculation of damages and key economic defenses in large-scale competition law cases.
- Search Strategy: Our refined strategy is to search the archives of these courts for judgments that specifically discuss the methodology of “damages quantification,” “economic modeling,” and, crucially, the “pass-on defense” in the context of competition claims.
- Supporting Online Intelligence: A search for legal commentary on “pass-on defence UK competition law” reveals numerous articles from law firms discussing how UK courts have treated this complex economic defense in landmark cases, such as the Sainsbury’s v Mastercard litigation.
- Expected Outcome: A legal brief detailing how UK courts handle the quantification of damages and the key economic defenses in competition cases. This intelligence is critical for preparing our own economic experts and for preemptively building legal and economic arguments to counter the defendants’ inevitable claims that the national health services did not suffer any actual loss.

62. Searchlink: `64816` (Internal Document)

The Standard Model: Internal files represent the core proprietary analysis or the central Unsolicited Proposal (USP) of a COCOO project ¹. All external intelligence gathering is designed to support, validate, and provide the evidence base for the contents of these internal documents ².
Customisation for the PFIZER CASE:
- Objective: To use the specific, confidential information within internal file 64816 to direct and focus our external investigation into the Pfizer/Flynn Pharma “excessive pricing” case.
- Search Strategy: The action is to retrieve the designated file from COCOO’s internal systems. For the purpose of this case, we will assume the file contains a detailed economic analysis or a confidential expert opinion that models the “but-for” price of phenytoin sodium capsules—the price that would have prevailed in a competitive market.
- Supporting Online Intelligence: Not applicable for an internal file.
- Expected Outcome: A highly targeted investigation plan based on the internal model’s data needs. All external research on platforms like www-gov-uk-search-advanced will be focused on finding the public data on NHS expenditure and prescription volumes needed to populate this economic model. This process turns our internal analysis into a fully evidenced expert report ready for litigation.

63. Searchlink: `www-ec-europa-eu-haveyoursay`

The Standard Model: The European Commission’s “Have your say” portal is a direct channel for COCOO to influence the direction of EU policy and to find stakeholder feedback on legislation ³.
Customisation for the PFIZER CASE:
- Objective: To find evidence of prior complaints or concerns raised by patient groups or health services across Europe about excessive pricing of off-patent medicines.
- Search Strategy: We will search the portal for any past public consultations on the “EU Pharmaceutical Strategy,” “access to medicines,” or “competition in the pharmaceutical sector.” Our strategy is to download and analyze the specific submissions made by pan-European patient groups (e.g., European Patients’ Forum) or hospital associations.
- Supporting Online Intelligence: An online search for “BEUC report on medicine prices” (BEUC is the European Consumer Organisation) will likely find public reports or summaries of their positions, helping to locate key documents and arguments.
- Expected Outcome: A report containing direct quotes and evidence from patient and consumer groups across Europe. This will prove that the harm caused by excessive pricing is a widespread, pan-European concern. This supports the public interest dimension of our case and demonstrates that our action against Pfizer is addressing a systemic problem.

64. Searchlink: `www-caselaw-nationalarchives-gov-uk`

The Standard Model: The National Archives case law service is a key resource for accessing judgments from various UK courts, particularly those involving challenges to public bodies ⁴.
Customisation for the PFIZER CASE:
- Objective: To find foundational UK case law on the legal test for “excessive pricing” as a form of abuse of a dominant position.
- Search Strategy: We will search the archives for landmark UK cases that have established the principles for determining when a price is so high that it becomes an illegal abuse. Keywords will include "excessive pricing", "abuse of dominance", "Chapter II prohibition", and "Competition Act 1998".
- Supporting Online Intelligence: Searching for legal commentary on UK cases like CMA v Flynn and Pfizer itself, as it has progressed through the courts, will provide expert analysis on how the legal tests for excessive pricing have been interpreted and applied by the highest UK courts.
- Expected Outcome: A foundational legal brief on the methodology for proving excessive pricing under UK competition law. This is essential for our legal team to structure their arguments and for instructing our economic experts on the specific evidence they need to provide to meet the legal tests established by the courts.

65. Searchlink: `www-violationtracker-uk`

The Standard Model: Violation Tracker UK is a comprehensive database of regulatory infringements and penalties in the UK, with a powerful advanced search function that allows filtering by Offence Group (e.g., competition-related offences, consumer-protection-related offences) ⁵.
Customisation for the PFIZER CASE:
- Objective: To investigate the broader compliance record of Pfizer and Flynn Pharma in the UK, looking for patterns of misconduct that go beyond this specific competition case.
- Search Strategy: Our refined strategy is to search Violation Tracker UK for the UK entities “Pfizer Limited” and “Flynn Pharma Limited”. We will broaden the search beyond just competition offences to include any “marketing and advertising offences,” “health-care-related offenses,” or “false claims/statements” violations.
- Supporting Online Intelligence: A search for “Pfizer fined UK” or “PMCPA Pfizer” can reveal past enforcement actions by UK bodies like the Prescription Medicines Code of Practice Authority (PMCPA) for breaches of the pharmaceutical marketing code.
- Expected Outcome: A comprehensive risk and compliance profile for each defendant company. A history of violations in other areas, such as illegal marketing, helps to build a compelling narrative of a corporate culture that prioritizes profits over rules. This narrative can be used strategically in the public relations campaign surrounding the case to frame the defendants as untrustworthy actors who have a history of exploiting the system.

66. Searchlink: `www-business-property-courts-uk`

The Standard Model: The model for the archives of the UK’s specialist Business and Property Courts is to search for judgments in high-value, complex commercial disputes that may provide persuasive precedents ⁶.
Customisation for the PFIZER CASE:
- Objective: To find UK case law that deals with the complex calculation of damages in large-scale competition law cases, specifically involving public bodies as claimants.
- Search Strategy: Our refined strategy is to search the archives of these courts for judgments that specifically discuss the methodology of “damages quantification” in claims brought by public or quasi-public entities. We are particularly interested in how the courts assess the “counterfactual” scenario—what would have happened without the illegal conduct.
- Supporting Online Intelligence: A search for legal commentary on “quantifying damages in public procurement litigation UK” will reveal articles discussing how courts approach these complex calculations, which often involve significant economic modeling.
- Expected Outcome: A legal brief detailing how UK courts handle the quantification of damages when the claimant is a public body like the NHS. This intelligence is critical for preparing our own economic experts and for ensuring our damages model is built on a solid legal and methodological foundation that the court will accept.

7. Searchlink: `www-db-comp-eu`

The Standard Model: The doctrine for db.comp.eu is to use it for rapid precedent analysis in EU competition law, particularly for mergers and State Aid cases, to understand the European Commission’s approach in specific sectors.
Customisation for the PFIZER CASE:
- Objective: To find all relevant EU competition law cases related to “excessive pricing” by dominant pharmaceutical companies, which will serve as legal and economic precedents for our UK-based claim.
- Search Strategy:
  - Use the db.comp.eu database search, filtering by “Case Instrument: Antitrust”.
  - Filter further by NACE Code: 21.20 (Manufacture of pharmaceutical preparations).
  - Use keywords in the full-text search: "excessive pricing", "unjustified price", "unfair prices", "pharmaceutical", and the names of companies from known cases like "Aspen".
- Supporting Online Intelligence: An online search for "European Commission excessive pricing pharmaceutical cases" confirms that the Aspen Pharma case (AT.39952) is the key precedent where the Commission investigated and secured commitments from a company over excessive price increases for off-patent cancer drugs. This gives us a specific case to analyze.
- Expected Outcome: A comprehensive list, with case numbers and summaries, of all EU “excessive pricing” antitrust cases in the pharmaceutical sector. The analysis from the Aspen case in particular will provide a detailed framework for how the Commission defines an excessive price and calculates the harm, which is a powerful persuasive precedent for our arguments before the UK courts.

8. Searchlink: `www-policy-trade-ec-europa-eu`

The Standard Model: The standard model for the EU’s trade policy portal is to conduct forensic keyword searches within the legal texts of EU trade agreements and official policy documents to identify legal risks and opportunities.
Customisation for the PFIZER CASE:
- Objective: To find high-level EU policy documents that establish the strategic importance of ensuring affordable medicines and promoting generic competition.
- Search Strategy:
  - Navigate to the sections of trade.ec.europa.eu and its linked internal market sites related to industrial strategy and health.
  - Search for the official Communication from the Commission titled the “Pharmaceutical Strategy for Europe.”
  - Perform a detailed keyword search within this and related documents for phrases like: "access to affordable medicines", "generic and biosimilar competition", "security of supply", and "value for money".
- Supporting Online Intelligence: A search for "Pharmaceutical Strategy for Europe official text" leads directly to the primary document (COM(2020) 761 final) published by the European Commission, which outlines these policy goals explicitly.
- Expected Outcome: A dossier of EU policy documents containing direct quotes from the European Commission. These quotes will be used to frame Pfizer’s actions as running directly contrary to the EU’s stated strategic public health and economic objectives, adding significant weight and public interest justification to our claim.

9. Searchlink: `www-eu-itas-by-nation`

The Standard Model: The procedure for the EU’s International Trade in Services (ITAS) database is to extract quantitative data to analyze service trade trends.
Customisation for the PFIZER CASE:
- Objective: To quantify the economic scale of the UK pharmaceutical market to provide a compelling context for the damages claim brought by the NHS.
- Search Strategy: As this platform is for services, our strategy is to pivot to associated EU statistical databases like Eurostat’s Comext, which are linked from this policy area. We will search the Comext database for detailed statistics on the total value (€) of “pharmaceutical products” (by their Combined Nomenclature codes) that are both imported into and manufactured within the United Kingdom annually over the last 10 years.
- Supporting Online Intelligence: We will cross-reference this data with reports from UK-based bodies, such as the Association of the British Pharmaceutical Industry (ABPI) or the Office for National Statistics (ONS), which publish their own data on the size of the UK pharmaceutical market. This helps to verify the Eurostat data.
- Expected Outcome: A detailed quantitative report showing the multi-billion-pound scale of the UK pharmaceutical market. This data is essential for demonstrating to the court the massive financial context in which Pfizer’s alleged overpricing occurred, highlighting the significance of the harm caused to the NHS budget.

10. Searchlink: `www-policy-trade-ec-europa-eu-2`

The Standard Model: The doctrine for the EU’s trade enforcement portal is to use its formal complaint mechanisms to challenge unfair trade barriers.
Customisation for the PFIZER CASE:
- Objective: This platform is of secondary relevance. The strategy is to creatively search for any instances where a country’s drug pricing and reimbursement system has been challenged as a form of trade barrier.
- Search Strategy: We will search the trade barrier database for any complaints filed by non-EU countries (particularly the US) against the EU or the UK. The search keywords will be "pharmaceutical pricing", "reimbursement", "price controls", and "market access for medicines".
- Supporting Online Intelligence: An online search for “PhRMA special 301 report” reveals annual reports where the US pharmaceutical lobby criticizes foreign price control systems, often framing them as barriers to trade and innovation.
- Expected Outcome: A report on whether pharmaceutical pricing systems have been framed as trade barriers in other contexts. This is a secondary line of inquiry but could provide valuable intelligence on the international policy arguments surrounding drug pricing. It helps us understand the playbook used by the pharmaceutical industry to challenge the very price regulations that Pfizer de-listed from in the UK.

11. Searchlink: `www-investegate`

The Standard Model: The standard model for Investegate is to use its platform and advanced search functions to monitor UK company announcements via the Regulatory News Service (RNS).
Customisation for the PFIZER CASE:
- Objective: To monitor the public statements and financial results of the major UK-listed pharmaceutical companies for any commentary on pricing pressures or competition investigations.
- Search Strategy:
  - Set up RNS monitoring alerts on Investegate for major UK pharmaceutical companies like GSK and AstraZeneca.
  - Use specific alert keywords: "CMA investigation", "pricing pressure", "generic competition", "phenytoin", and "epilepsy".
- Supporting Online Intelligence: We will supplement this by reviewing the “Legal Proceedings” and “Risk Factors” sections of these companies’ latest annual reports, which are often available on their corporate websites via a search. This can provide details on significant ongoing litigation or regulatory risks.
- Expected Outcome: An early-warning system. An RNS announcement from a major competitor about a new CMA pricing investigation, or commentary in their financial results about the impact of generic competition on their revenues, would provide valuable, real-time contextual evidence for our own case against Pfizer.

1. Searchlink: `www-publicsector-co-uk`

The Standard Model: The model for this platform is to use it as a directory to identify and target key contacts within the UK public sector, particularly for initiating contact regarding public contracts or regulatory matters¹¹¹¹.
Customisation for the PFIZER CASE:
- Objective: To identify the specific officials and departments within the UK’s National Health Service (NHS) who were responsible for the budget that was overcharged for phenytoin sodium capsules. These are our primary clients for the public contract proposal.
- Search Strategy:
  - Use the publicsector.co.uk directory search.
  - Search for job titles such as: "Head of Medicines Value", "Pharmaceutical Procurement Manager", "Specialised Commissioning Lead", and "Neurology Budget Holder".
  - Filter by organisation: “NHS England”, “Department of Health and Social Care”.
- Supporting Online Intelligence: A search for “NHS Commercial Medicines Directorate leadership chart” or “NHS England specialised commissioning neurology” helps to identify the names of the specific internal bodies and senior personnel responsible for these decisions, which can then be cross-referenced in the directory.
- Expected Outcome: A detailed stakeholder map and target list of the key public officials within the NHS who were financially impacted by the price hike. This list is the essential first step for our engagement and for presenting our “Unsolicited Proposal” to the correct decision-makers.

2. Searchlink: `www-gov-uk-search-advanced`

The Standard Model: The model for gov.uk is to use its advanced search capabilities to locate specific policy documents, official reports, and public datasets published by UK government bodies to hold those entities to account²²²².
Customisation for the PFIZER CASE:
- Objective: To find official UK government data and reports that quantify the financial harm to the NHS caused by the phenytoin price hike.
- Search Strategy:
  - Use the advanced search on gov.uk.
  - Use exact phrase searches for "phenytoin sodium" and "NHS medicine spending".
  - Combine with keywords like "CMA", "competition", "overcharge", and "epilepsy".
  - Filter results by document type: “Impact assessment”, “Policy paper”, “Research and analysis”.
  - Filter by publishing organisation: “National Audit Office”, “Department of Health and Social Care”, “Competition and Markets Authority”.
- Supporting Online Intelligence: A search for “National Audit Office report on NHS prescription drug costs” or “Health Select Committee inquiry generic medicines” will identify major official reports that have analyzed this exact issue, providing key document titles to search for.
- Expected Outcome: A dossier of official UK government publications. This will include reports from the NAO quantifying unnecessary expenditure, and potentially impact assessments from the Department of Health. This dossier will form the core, undeniable evidence base for calculating the damages in our legal claim.

3. & 4. Searchlinks: `www-e-justice-europa-eu-advancedsearch` and `e-justice.europa.eu/topics/registers...`

The Standard Model: The model for the EU e-Justice portal is to leverage its interconnection of national business registers to find official corporate information on companies registered within any EU member state³³.
Customisation for the PFIZER CASE:
- Objective: To identify the precise, official European corporate entities for both Pfizer and Flynn Pharma, who are the defendants in our case.
- Search Strategy: We will use the portal’s “Find a Company” function, which searches across interconnected EU and UK business registers. We will perform searches for:
  - “Pfizer Limited” (the likely UK entity)
  - “Flynn Pharma Limited” (the likely UK entity)
  - Any other known European subsidiaries of Pfizer Inc. (e.g., in Ireland, Netherlands).
- Supporting Online Intelligence: The CMA’s original press release on the Pfizer/Flynn case explicitly names the defendant companies as “Pfizer Inc. and Flynn Pharma Ltd”. This gives us the exact names to use in our search on the e-Justice portal to pull their official corporate details.
- Expected Outcome: A definitive list of the correct legal defendants for our lawsuit, including their registered company numbers, official addresses for serving legal documents, and current corporate status. This is a non-negotiable legal prerequisite for initiating the claim.

5. Searchlink: `www-competition-cases-ec-europa-eu-searchcaseinstrumentsa`

The Standard Model: The model for the EC Competition case search portal is to track enforcement actions and find precedents by filtering for cases by type (Antitrust, Merger, State Aid), company name, and NACE code⁴⁴⁴⁴.
Customisation for the PFIZER CASE:
- Objective: To find European Commission precedents for tackling “excessive pricing” by dominant pharmaceutical companies, which supports the legal theory of our case.
- Search Strategy: Although our primary case is based on a UK CMA decision, finding parallel EU cases strengthens our position. We will search the EC case database, filtering for “Antitrust” cases in the “Pharmaceuticals” sector. We will use keywords like "excessive pricing" and "abuse of dominance".
- Supporting Online Intelligence: An online search for “European Commission Aspen Pharma case” reveals a key precedent (Case AT.40394) where the Commission investigated a company for price increases of up to several hundred percent for off-patent cancer medicines.
- Expected Outcome: A report on EU legal precedents for excessive pricing cases in the pharmaceutical sector. The Aspen case, in particular, provides a powerful parallel. We can analyze the Commission’s legal reasoning and economic analysis in that case to inform and strengthen our own arguments against Pfizer before the UK courts.

RESUMEN DEL CASO PFIZER

Problema Central: El “Caso Pfizer” es una acción legal estratégica de COCOO centrada en un presunto abuso de posición dominante por parte de la compañía farmacéutica Pfizer. El núcleo del caso es una reclamación de daños y perjuicios en nombre del Servicio Nacional de Salud del Reino Unido (NHS) ¹ debido a la imposición de precios excesivos e injustos para un medicamento anticonvulsivo esencial, las cápsulas de fenitoína sódica². La Autoridad de Competencia y Mercados del Reino Unido (CMA) ya ha determinado en una decisión de infracción que Pfizer y su distribuidor, Flynn Pharma, abusaron de su posición dominante al aumentar el precio del medicamento hasta en un 2,600% de la noche a la mañana después de que fuera descalificado del esquema de regulación de precios³.

El Daño: El perjuicio es un sobrecoste masivo y directo para el erario público. El NHS, el principal comprador del medicamento, se vio obligado a pagar un precio extraordinariamente inflado por un fármaco antiguo pero esencial para aproximadamente 48,000 pacientes en el Reino Unido, gastando decenas de millones de libras de más⁴. Este dinero podría haberse destinado a otros tratamientos y servicios para pacientes.
La Propuesta de COCOO (USP): La estrategia central de COCOO es la presentación de un “Proyecto de Contratación Pública” al NHS. En esta Propuesta No Solicitada (USP), COCOO se ofrece para gestionar y financiar una acción legal de “seguimiento” (follow-on) por daños y perjuicios contra Pfizer y Flynn Pharma. COCOO asumiría todos los costes y riesgos del complejo litigio, incluyendo la contratación de los mejores equipos legales y peritos económicos, a cambio de un porcentaje de la indemnización recuperada⁵⁵. Esto permite al NHS recuperar los fondos públicos perdidos sin ningún coste o riesgo para el contribuyente⁶.
Metodología: El caso se basa en tres pilares:
1. Acción Legal de Seguimiento: Aprovechar la decisión de infracción de la CMA como prueba vinculante de la conducta ilegal, centrando el litigio únicamente en la cuantificación de los daños⁷.
2. Análisis Económico Pericial: La fase de investigación se centra en construir un modelo económico robusto para calcular el “sobrecoste” exacto sufrido por el NHS⁸.
3. Campaña Mediática y de Comunicación: Lanzar una campaña mediática para enmarcar el caso como una acción de recuperación de fondos para el contribuyente, destacando el precio “escandaloso” y el impacto en el presupuesto de la sanidad pública⁹.

Actores Clave y sus Intereses

NHS (National Health Service): Es la principal víctima del sobrecoste y el cliente/demandante principal. Su interés es recuperar las decenas de millones de libras pagadas de más para reinvertirlas en la atención al paciente. Sin embargo, puede tener una capacidad o un apetito por el riesgo limitados para emprender litigios complejos por sí mismo¹⁰.
Pfizer y Flynn Pharma: Son los demandados y los infractores de la ley de competencia. Su interés es minimizar o evitar por completo el pago de la indemnización. Utilizarán sus vastos recursos para luchar contra la reclamación en los tribunales, probablemente argumentando que el sobrecoste fue menor de lo reclamado o que el NHS no sufrió un daño real¹¹.
CMA (Competition and Markets Authority): Es el regulador que emitió la decisión de infracción original. Su interés es que sus decisiones sean ratificadas por los tribunales y que las víctimas de las infracciones que identifica obtengan una compensación efectiva, ya que esto valida y refuerza el efecto disuasorio de su trabajo.
COCOO: Es el arquitecto, financiador y gestor del caso. Su interés es conseguir el contrato público del NHS para gestionar la reclamación. El éxito en este caso de alto perfil validaría su modelo de negocio, generaría ingresos significativos y establecería a COCOO como el socio preferente para los organismos públicos que buscan recuperar daños por infracciones de la competencia¹².

Análisis Estratégico y Perspectivas Profesionales (Mis `Insights`)

Este caso es un ejemplo clásico y potente de litigación de “seguimiento” por daños y perjuicios, un área de especialización clave para COCOO.

Fortalezas del Caso:
- Base Legal Extremadamente Sólida: El mayor obstáculo en un caso de competencia, probar la infracción, ya ha sido superado por la CMA. La decisión de la CMA establece la responsabilidad, dejando que el litigio se centre principalmente en la cuantía (quantum) de los daños. Esto reduce enormemente el riesgo legal.
- Daño Claro y Cuantificable: El perjuicio no es teórico. Es un sobrecoste financiero directo que se puede calcular comparando el precio pagado por el NHS con el precio anterior al aumento. Los datos necesarios para este cálculo (precios y volúmenes de compra) deberían estar disponibles en los registros del NHS.
- Demandante y Causa de Interés Público: El demandante es el servicio nacional de salud, una de las instituciones más valoradas del Reino Unido. La causa —recuperar dinero de los contribuyentes de una gran farmacéutica que cobró un precio excesivo— tiene un enorme atractivo para el público y los medios de comunicación, lo que crea una presión reputacional significativa sobre los demandados.
- Modelo de Negocio Atractivo: La propuesta de “riesgo cero” para el NHS, donde COCOO y sus financiadores asumen todos los costes, es extremadamente persuasiva para un organismo público con presupuestos ajustados.
Debilidades y Riesgos:
- Batalla de Peritos Económicos: El punto central del litigio será la “batalla de los peritos” para determinar la cuantía exacta del sobrecoste. Pfizer contratará a los economistas más caros y prestigiosos para argumentar que el daño fue mínimo. Ganar esta batalla requiere una inversión significativa en los mejores peritos económicos y un modelo de daños inexpugnable.
- Litigación Larga y Costosa: A pesar de la sólida base legal, Pfizer tiene los recursos para apelar cada decisión y utilizar todas las tácticas procesales posibles para alargar el caso durante años. La financiación debe estar asegurada para una guerra de desgaste legal a largo plazo.
- Riesgo de Apelación de la Decisión Original: Siempre existe el riesgo, aunque sea pequeño, de que la decisión original de la CMA sea anulada o modificada en apelación ante el Tribunal de Apelación de la Competencia (CAT) o tribunales superiores. Esto es el principal riesgo externo al caso de daños en sí mismo.
Recomendaciones para los Próximos Pasos y Refinamiento de la Estrategia:
- Asegurar el Mandato del NHS: El primer paso es formalizar el contrato con el NHS. Esto requiere una comunicación clara y persuasiva con los responsables de la dirección jurídica y comercial del NHS, presentando el caso como una recuperación de activos de “riesgo cero”.
- Construir el “Equipo de Ensueño”: Inmediatamente después, se debe contratar al mejor equipo posible: un bufete de abogados líder en litigios de competencia en el Reino Unido y una de las principales consultoras de economía de la competencia para que empiecen a construir el modelo de daños.
- Controlar la Narrativa Mediática: La campaña mediática, como se describe en https://pfizer.cocoo.uk/media-campaign/, debe lanzarse de forma coordinada con la presentación de la demanda. El mensaje debe ser simple y centrado en el contribuyente: “Recuperando nuestro dinero para la sanidad”. Se debe evitar que la narrativa se desvíe hacia un ataque general contra la industria farmacéutica.
- Estrategia de Búsqueda: Nuestras búsquedas en los searchlinks deben ahora centrarse en: 1) Encontrar todas las sentencias y documentos del litigio de apelación de Pfizer contra la decisión de la CMA en los portales legales del Reino Unido (CAT, BAILII). 2) Cuantificar el gasto del NHS en fenitoína utilizando informes del NAO y datos de salud en gov.uk. 3) Construir perfiles de los equipos legales y de los peritos económicos que Pfizer ha utilizado en casos de competencia anteriores, utilizando bases de datos legales y de noticias.

En conclusión, el “Caso Pfizer” es un proyecto con una probabilidad de éxito muy alta debido a la decisión previa de la CMA. Representa una oportunidad ideal para demostrar el valor del modelo de negocio de COCOO, recuperando una suma muy significativa para el servicio público y estableciendo un importante precedente. El éxito depende de la excelencia en la ejecución del litigio y en la gestión de una compleja batalla de peritos económicos.

HAZTE MIEMBRO GRATIS PROYECTOS ABIERTOS QUIENES SOMOS MEDIACION DIPLOMACIA DONACIONES PRIVACIDAD CONDICIONES

CASELINKS

Batch 17 of 28

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

92. Searchlink: www-pacer-usa

93. Searchlink: www-usaspending-gov

94. Searchlink: www-global-branddb-wipo-int

95. Searchlink: www-register-openownership-org-search

96. Searchlink: www-infocif-es

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

82, 83, 84 & 85. Searchlinks: www-bidstats-uk, www-oscartool-gov-uk, and their associated links

86. Searchlink: www-wto-disp-settlement

87. Searchlink: www-uk-parlm-petitions

88. Searchlink: www-usa-oge-gov

89. Searchlink: www-usa-congress-lobby-discl

90. & 91. Searchlinks: www-espacenet-global-patents and www-ppubs-uspto-patents

67. Searchlink: www-casetracker-gov-uk

68. Searchlink: www.hl.co.uk/funds

69. Searchlink: www-causelist-gov-uk

70. Searchlink: www-find-tender-service-gov-uk

71. Searchlink: www-lobbyfacts-eu

82, 83, 84 & 85. Searchlinks: www-bidstats-uk, www-oscartool-gov-uk, and their associated links

86. Searchlink: www-wto-disp-settlement

67. Searchlink: www-casetracker-gov-uk

68. Searchlink: www.hl.co.uk/funds

69. Searchlink: www-causelist-gov-uk

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

92. Searchlink: `www-pacer-usa`

93. Searchlink: `www-usaspending-gov`

94. Searchlink: `www-global-branddb-wipo-int`

95. Searchlink: `www-register-openownership-org-search`

96. Searchlink: `www-infocif-es`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

82, 83, 84 & 85. Searchlinks: `www-bidstats-uk`, `www-oscartool-gov-uk`, and their associated links

86. Searchlink: `www-wto-disp-settlement`

87. Searchlink: `www-uk-parlm-petitions`

88. Searchlink: `www-usa-oge-gov`

89. Searchlink: `www-usa-congress-lobby-discl`

90. & 91. Searchlinks: `www-espacenet-global-patents` and `www-ppubs-uspto-patents`

67. Searchlink: `www-casetracker-gov-uk`

68. Searchlink: `www.hl.co.uk/funds`

69. Searchlink: `www-causelist-gov-uk`

70. Searchlink: `www-find-tender-service-gov-uk`

71. Searchlink: `www-lobbyfacts-eu`

82, 83, 84 & 85. Searchlinks: `www-bidstats-uk`, `www-oscartool-gov-uk`, and their associated links

86. Searchlink: `www-wto-disp-settlement`

67. Searchlink: `www-casetracker-gov-uk`

68. Searchlink: `www.hl.co.uk/funds`

69. Searchlink: `www-causelist-gov-uk`

70. Searchlink: `www-find-tender-service-gov-uk`

71. Searchlink: `www-lobbyfacts-eu`

67. Searchlink: `www-casetracker-gov-uk`